, Tracking Stock Market Picks
Enter Symbol:
IsoRay Inc. (ISR) [hlAlert]

up 23.42 %

IsoRay Inc. (ISR) rated Buy with price target $1.70 by C.K. Cooper

Posted on: Wednesday,  Mar 17, 2010  8:25 AM ET by C.K. Cooper

C.K. Cooper rated Buy IsoRay Inc. (AMEX: ISR) on 03/17/2010, when the stock price was $1.11. Since
then, IsoRay Inc. has gained 23.42% as of 08/27/2015's recent price of $1.37.
If you would have followed this C.K. Cooper's recommendation on ISR, you would have gained 23.42% of your investment in 1989 days.

IsoRay, Inc. is engaged in the development of permanent seed brachytherapy in the treatment of cancers. IsoRay, Inc. has obtained clearance from the United States Food and Drug Administration (FDA) for treatment for all solid tumor applications using Cesium-131 (Cs-131). Such applications include prostate cancer; ocular melanoma; head, neck and lung tumors; and breast, liver, brain and pancreatic cancer. The seed may be used in surface, interstital and intracavity applications for tumors with known radio sensitivity. On June 1, 2009, the Company expanded its application of Cs-131 with the treatment of a head and neck tumor that could not be accessed by other treatment modalities. IsoRay International LLC (International) is a wholly owned subsidiary of the Company. During fiscal year ended June 30, 2009, the Company divested its ownership in the Russian LLC.

C. K. Cooper & Company has for over a decade provided insightful research ideas and commentary. As the firm identifies focus industries it brings together an analytical team to provide unique vision and insight to select investment ideas. In addition, leveraging on the expertise of the firm, the Research Team can evaluate opportunities against a wide database of industry and competitive trends.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/17/2010 8:25 AM Buy
1.11 1.70
as of 12/31/2010
1 Week up  9.56 %
1 Month down  -5.97 %
3 Months up  0.80 %
1 YTD up  13.51 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy